Genotype- vs Phenotype-Guided Approaches to Improve ATTR Detection.
作者信息
Regan Jessica A, Fontana Marianna, Selvaraj Senthil
机构信息
Division of Cardiology, Duke University School of Medicine, Durham, North Carolina.
Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, North Carolina.
出版信息
JAMA Cardiol. 2024 Nov 1;9(11):957-959. doi: 10.1001/jamacardio.2024.2654.
Abstract
摘要
相似文献
1
Genotype- vs Phenotype-Guided Approaches to Improve ATTR Detection.改善转甲状腺素蛋白淀粉样变性检测的基因型与表型引导方法
JAMA Cardiol. 2024 Nov 1;9(11):957-959. doi: 10.1001/jamacardio.2024.2654.
2
Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement.揭示老年重度主动脉瓣狭窄行经导管主动脉瓣置换术患者中的转甲状腺素蛋白心脏淀粉样变性及其预测因素。
Eur Heart J. 2017 Oct 7;38(38):2879-2887. doi: 10.1093/eurheartj/ehx350.
3
Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis - Report from the Transthyretin Amyloidosis Outcome Survey (THAOS).转甲状腺素蛋白淀粉样变性患者的基因型和表型对心脏生物标志物的影响——转甲状腺素蛋白淀粉样变性结局调查（THAOS）报告
PLoS One. 2017 Apr 6;12(4):e0173086. doi: 10.1371/journal.pone.0173086. eCollection 2017.
4
The Impact of Active Ascertainment on Sex-Specific Differences in the Prevalence and Phenotype of Transthyretin Cardiac Amyloidosis: The Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations Study.主动确诊对转甲状腺素蛋白心脏淀粉样变患病率和表型的性别差异的影响：少数族裔人群心脏淀粉样变核素成像筛查研究
Am J Cardiol. 2025 Feb 15;237:60-64. doi: 10.1016/j.amjcard.2024.11.019. Epub 2024 Nov 23.
5
Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey).转甲状腺素蛋白心脏淀粉样变性的基因型与表型：THAOS（转甲状腺素蛋白淀粉样变性结局调查）
J Am Coll Cardiol. 2016 Jul 12;68(2):161-72. doi: 10.1016/j.jacc.2016.03.596.
6
Clinical and genetic profiles of hereditary transthyretin amyloidosis in Taiwan.台湾遗传性转甲状腺素蛋白淀粉样变性的临床和遗传特征。
Ann Clin Transl Neurol. 2019 Apr 9;6(5):913-922. doi: 10.1002/acn3.778. eCollection 2019 May.
7
Clinical Phenotype and Prognosis of Asymptomatic Patients With Transthyretin Cardiac Amyloid Infiltration.转甲状腺素蛋白心脏淀粉样变浸润无症状患者的临床表型与预后
JAMA Cardiol. 2025 May 1;10(5):437-445. doi: 10.1001/jamacardio.2024.5221.
8
Phenotype and prognostic factors in geriatric and non-geriatric patients with transthyretin cardiomyopathy.转甲状腺素蛋白心肌病老年和非老年患者的表型及预后因素
ESC Heart Fail. 2024 Dec;11(6):3814-3832. doi: 10.1002/ehf2.14793. Epub 2024 Jul 17.
9
Diversity of heart failure phenotypes in transthyretin amyloid cardiomyopathy. More than just heart failure with preserved ejection fraction.转甲状腺素蛋白淀粉样变心肌病中心力衰竭表型的多样性。不只是射血分数保留的心力衰竭。
Ann Med. 2024 Dec;56(1):2418965. doi: 10.1080/07853890.2024.2418965. Epub 2024 Oct 26.
10
Detection of transthyretin amyloid cardiomyopathy by automated data extraction from electronic health records.从电子健康记录中自动提取数据检测转甲状腺素蛋白淀粉样心肌病。
ESC Heart Fail. 2023 Dec;10(6):3483-3492. doi: 10.1002/ehf2.14517. Epub 2023 Sep 19.
引用本文的文献
1
Hereditary Transthyretin Cardiac Amyloidosis With the p.V142I Variant: Mechanistic Insights and Diagnostic Challenges.携带p.V142I变异的遗传性转甲状腺素蛋白心脏淀粉样变性：机制见解与诊断挑战
Circ Heart Fail. 2025 Jun;18(6):e012469. doi: 10.1161/CIRCHEARTFAILURE.124.012469. Epub 2025 Mar 14.
本文引用的文献
1
Prevalence, Cardiac Phenotype, and Outcomes of Transthyretin Variants in the UK Biobank Population.英国生物库人群中转甲状腺素变体的流行率、心脏表型和结局。
JAMA Cardiol. 2024 Nov 1;9(11):964-972. doi: 10.1001/jamacardio.2024.2190.
2
Cardiovascular Burden of the V142I Transthyretin Variant.载脂蛋白 V142I 变异的心血管负担。
JAMA. 2024 Jun 4;331(21):1824-1833. doi: 10.1001/jama.2024.4467.
3
Actionable Genotypes and Their Association with Life Span in Iceland.冰岛具有可操作基因型与寿命的关联分析。
N Engl J Med. 2023 Nov 9;389(19):1741-1752. doi: 10.1056/NEJMoa2300792.
4
Age Dependency of Cardiovascular Outcomes With the Amyloidogenic pV142I Transthyretin Variant Among Black Individuals in the US.美国黑人群体中淀粉样变 pV142I 转甲状腺素变体的心血管结局的年龄依赖性。
JAMA Cardiol. 2023 Aug 1;8(8):784-788. doi: 10.1001/jamacardio.2023.1525.
5
Design and Rationale the SCAN-MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study.SCAN-MP（少数民族人群核医学心肌淀粉样变筛查研究）的设计和原理。
J Am Heart Assoc. 2023 Apr 18;12(8):e028534. doi: 10.1161/JAHA.122.028534. Epub 2023 Apr 17.
6
RNA-targeting and gene editing therapies for transthyretin amyloidosis.针对转甲状腺素蛋白淀粉样变性的 RNA 靶向和基因编辑疗法。
Nat Rev Cardiol. 2022 Oct;19(10):655-667. doi: 10.1038/s41569-022-00683-z. Epub 2022 Mar 23.
7
Clinical Implications of the Amyloidogenic V122I Transthyretin Variant in the General Population.人群中淀粉样变 V122I 转甲状腺素变体的临床意义。
J Card Fail. 2022 Mar;28(3):403-414. doi: 10.1016/j.cardfail.2021.09.015. Epub 2021 Oct 9.
8
ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG).美国医学遗传学与基因组学学会（ACMG）关于临床外显子组和基因组测序中次要发现报告的ACMG SF v3.0清单：一项政策声明
Genet Med. 2021 Aug;23(8):1381-1390. doi: 10.1038/s41436-021-01172-3. Epub 2021 May 20.
9
A machine learning model for identifying patients at risk for wild-type transthyretin amyloid cardiomyopathy.一种用于识别野生型转甲状腺素蛋白淀粉样心肌病风险患者的机器学习模型。
Nat Commun. 2021 May 11;12(1):2725. doi: 10.1038/s41467-021-22876-9.
10
Atrial Fibrillation and Ischemic Stroke With the Amyloidogenic V122I Transthyretin Variant Among Black Americans.美国黑人中伴有淀粉样变V122I转甲状腺素蛋白变异体的心房颤动和缺血性卒中
J Am Coll Cardiol. 2021 Jul 6;78(1):89-91. doi: 10.1016/j.jacc.2021.04.042. Epub 2021 May 3.
Zotero 插件